{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:02:16Z","timestamp":1773151336379,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier","isbn-type":[{"value":"9780128186718","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.mie.2019.05.051","type":"book-chapter","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T21:34:46Z","timestamp":1560807286000},"page":"361-381","source":"Crossref","is-referenced-by-count":22,"title":["In vitro assay for the development of small molecule inhibitors targeting PD-1\/PD-L1"],"prefix":"10.1016","author":[{"given":"Wenjie","family":"Zhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuman","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangfeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.mie.2019.05.051_bb0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1039\/C5AY03064A","article-title":"Green fluorescent protein-based assays for high-throughput functional characterization and ligand-binding studies of biotin protein ligase","volume":"8","author":"Askin","year":"2016","journal-title":"Analytical Methods"},{"key":"10.1016\/bs.mie.2019.05.051_bb0015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0020","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mie.2019.05.051_bb0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/ja209057d","article-title":"kinITC: A new method for obtaining joint thermodynamic and kinetic data by isothermal titration calorimetry","volume":"134","author":"Burnouf","year":"2012","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/bs.mie.2019.05.051_bb0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"10.1016\/bs.mie.2019.05.051_bb0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00216-013-6931-0","article-title":"NMR-based analysis of protein-ligand interactions","volume":"406","author":"Cala","year":"2014","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"10.1016\/bs.mie.2019.05.051_bb0040","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking of the PD-1\/PD-L1 interaction by a d-peptide antagonist for cancer immunotherapy","volume":"54","author":"Chang","year":"2015","journal-title":"Angewandte Chemie International Edition"},{"key":"10.1016\/bs.mie.2019.05.051_bb0045","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0050","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1158\/1538-7445.AM2015-5440","article-title":"Abstract 5440: Novel PD-1 blockade bioassay to assess therapeutic antibodies in PD-1 and PD-L1 immunotherapy programs","volume":"75","author":"Cheng","year":"2015","journal-title":"Cancer Research"},{"key":"10.1016\/bs.mie.2019.05.051_bb0055","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"10.1016\/bs.mie.2019.05.051_bb0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.it.2018.08.004","article-title":"Hiding in plain sight: Soluble immunomodulatory receptors","volume":"39","author":"Dahal","year":"2018","journal-title":"Trends in Immunology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.mie.2019.05.051_bb0070","doi-asserted-by":"crossref","first-page":"e86014","DOI":"10.1172\/jci.insight.86014","article-title":"T cell Bim levels reflect responses to anti-PD-1 cancer therapy","volume":"1","author":"Dronca","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/bs.mie.2019.05.051_bb0075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/978-1-4939-2425-7_35","article-title":"Fluorescence polarization assay to quantify protein-protein interactions in an HTS format","volume":"1278","author":"Du","year":"2015","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12964-018-0239-9","article-title":"The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)","volume":"16","author":"Du","year":"2018","journal-title":"Cell Communication and Signaling"},{"key":"10.1016\/bs.mie.2019.05.051_bb0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/bs.mie.2015.08.026","article-title":"Extending ITC to kinetics with kinITC","volume":"567","author":"Dumas","year":"2016","journal-title":"Methods in Enzymology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0090","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/adt.2006.4.583","article-title":"Label-free cell-based assays with optical biosensors in drug discovery","volume":"4","author":"Fang","year":"2006","journal-title":"Assay and Drug Development Technologies"},{"key":"10.1016\/bs.mie.2019.05.051_bb0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunological Reviews"},{"key":"10.1016\/bs.mie.2019.05.051_bb0100","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.2174\/1381612823666171004120152","article-title":"PD-1\/PD-L1 inhibitors for immuno-oncology: From antibodies to small molecules","volume":"23","author":"Geng","year":"2018","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/bs.mie.2019.05.051_bb0105","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"International Immunology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood-2006-12-062422","article-title":"Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells","volume":"110","author":"Goldberg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/bs.mie.2019.05.051_bb0115","first-page":"3309","article-title":"Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma","volume":"25","author":"He","year":"2005","journal-title":"Anticancer Research"},{"key":"10.1016\/bs.mie.2019.05.051_bb0120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.mie.2019.05.051_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev-biophys-070816-033701","article-title":"Structures of large protein complexes determined by nuclear magnetic resonance spectroscopy","volume":"46","author":"Huang","year":"2017","journal-title":"The Annual Review of Biophysics"},{"key":"10.1016\/bs.mie.2019.05.051_bb0130","doi-asserted-by":"crossref","first-page":"64892","DOI":"10.18632\/oncotarget.17615","article-title":"A cellular platform for the evaluation of immune checkpoint molecules","volume":"8","author":"Jutz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.mie.2019.05.051_bb0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-017-00612-6","article-title":"NFATc1 controls the cytotoxicity of CD8(+) T cells","volume":"8","author":"Klein-Hessling","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/bs.mie.2019.05.051_bb0140","first-page":"1676","article-title":"Peptide-conjugated nanoparticles reduce positive co-stimulatory expression and T cell activity to induce tolerance","volume":"25","author":"Kuo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.mie.2019.05.051_bb0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/17460441.2011.537322","article-title":"Fluorescence polarization assays in small molecule screening","volume":"6","author":"Lea","year":"2011","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/bs.mie.2019.05.051_bb0150","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1111\/cas.13666","article-title":"High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Science"},{"key":"10.1016\/bs.mie.2019.05.051_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/2326-6066.CIR-17-0035","article-title":"Peptide blocking of PD-1\/PD-L1 interaction for cancer immunotherapy","volume":"6","author":"Li","year":"2018","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.mie.2019.05.051_bb0160","doi-asserted-by":"crossref","first-page":"88360","DOI":"10.18632\/oncotarget.21729","article-title":"High-affinity human PD-L1 variants attenuate the suppression of T cell activation","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.mie.2019.05.051_bb0165","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.intimp.2015.12.039","article-title":"A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity","volume":"31","author":"Luan","year":"2016","journal-title":"International Immunopharmacology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0170","doi-asserted-by":"crossref","first-page":"13732","DOI":"10.1002\/anie.201707707","article-title":"Bioactive macrocyclic inhibitors of the PD-1\/PD-L1 immune checkpoint","volume":"56","author":"Magiera-Mularz","year":"2017","journal-title":"Angewandte Chemie International Edition"},{"key":"10.1016\/bs.mie.2019.05.051_bb0175","doi-asserted-by":"crossref","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging","volume":"112","author":"Maute","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.mie.2019.05.051_bb0180","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.tibs.2009.07.004","article-title":"Observing biological dynamics at atomic resolution using NMR","volume":"34","author":"Mittermaier","year":"2009","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/bs.mie.2019.05.051_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/9780470559277.ch090102","article-title":"Fluorescence polarization (FP) assays for monitoring peptide-protein or nucleic acid-protein binding","volume":"1","author":"Moerke","year":"2009","journal-title":"Current Protocols in Chemical Biology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0190","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nature Protocols"},{"key":"10.1016\/bs.mie.2019.05.051_bb0195","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jviromet.2012.11.004","article-title":"Fluorescence polarization-based assay using N-glycan-conjugated quantum dots for screening in hemagglutinin blockers for influenza A viruses","volume":"187","author":"Okamatsu","year":"2013","journal-title":"Journal of Virological Methods"},{"key":"10.1016\/bs.mie.2019.05.051_bb0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10408347.2014.881250","article-title":"Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis","volume":"45","author":"Olaru","year":"2015","journal-title":"Critical Reviews in Analytical Chemistry"},{"key":"10.1016\/bs.mie.2019.05.051_bb0205","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0210","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.str.2016.06.026","article-title":"Structure and dynamics of PD-L1 and an ultra-high-affinity PD-1 receptor mutant","volume":"24","author":"Pascolutti","year":"2016","journal-title":"Structure"},{"key":"10.1016\/bs.mie.2019.05.051_bb0215","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/slct.201800095","article-title":"Identification of small-molecule inhibitors of PD-1\/PD-L1 protein-protein interaction","volume":"3","author":"Patil","year":"2018","journal-title":"ChemistrySelect"},{"key":"10.1016\/bs.mie.2019.05.051_bb0220","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/bs.mie.2019.05.051_bb0225","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.mie.2019.05.051_bb0230","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: From enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"10.1016\/bs.mie.2019.05.051_bb0235","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40259-018-0303-4","article-title":"Small-molecule immune checkpoint inhibitors targeting PD-1\/PD-L1 and other emerging checkpoint pathways","volume":"32","author":"Sasikumar","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/bs.mie.2019.05.051_bb0240","article-title":"Preclinical development of ipilimumab and nivolumab combination immunotherapy: Mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology","volume":"11","author":"Selby","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.mie.2019.05.051_bb0245","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1517\/17460441.2013.806479","article-title":"Recent developments in the use of differential scanning fluorometry in protein and small molecule discovery and characterization","volume":"8","author":"Simeonov","year":"2013","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/bs.mie.2019.05.051_bb0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1041","article-title":"2018 Nobel prize in physiology or medicine","volume":"7","author":"Smyth","year":"2018","journal-title":"Clinical & Translational Immunology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0260","doi-asserted-by":"crossref","first-page":"19.25.1","DOI":"10.1002\/0471140864.ps1925s79","article-title":"Measuring protein-protein and protein-nucleic acid interactions by biolayer interferometry","volume":"79","author":"Sultana","year":"2015","journal-title":"Current Protocols in Protein Science"},{"key":"10.1016\/bs.mie.2019.05.051_bb0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-4939-2425-7_11","article-title":"Characterization of protein-protein interactions by isothermal titration calorimetry","volume":"1278","author":"Velazquez-Campoy","year":"2015","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0270","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1084\/jem.20021752","article-title":"Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction","volume":"197","author":"Wang","year":"2003","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.mie.2019.05.051_bb0275","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.mie.2019.05.051_bb0280","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jpba.2017.05.011","article-title":"Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1\/anti-PD-L1 therapeutic antibodies","volume":"145","author":"Wang","year":"2017","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/bs.mie.2019.05.051_bb0285","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/eji.201242529","article-title":"The soluble isoform of CTLA-4 as a regulator of T-cell responses","volume":"43","author":"Ward","year":"2013","journal-title":"European Journal of Immunology"},{"key":"10.1016\/bs.mie.2019.05.051_bb0290","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cmdc.201500566","article-title":"Cancer immunotherapy: Selected targets and small-molecule modulators","volume":"11","author":"Weinmann","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/bs.mie.2019.05.051_bb0295","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ncomms1093","article-title":"Protein-binding assays in biological liquids using microscale thermophoresis","volume":"1","author":"Wienken","year":"2010","journal-title":"Nature Communications"},{"key":"10.1016\/bs.mie.2019.05.051_bb0300","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13659-018-0177-7","article-title":"Small-molecule targets in tumor immunotherapy","volume":"8","author":"Zhu","year":"2018","journal-title":"Natural Products and Bioprospecting"},{"key":"10.1016\/bs.mie.2019.05.051_bb0305","doi-asserted-by":"crossref","first-page":"13049","DOI":"10.1002\/chem.201802599","article-title":"KinITC-one method supports both thermodynamic and kinetic SARs as exemplified on FimH antagonists","volume":"24","author":"Zihlmann","year":"2018","journal-title":"Chemistry-A European Journal"}],"container-title":["Methods in Enzymology","Tumor Immunology and Immunotherapy \u2013 Molecular Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0076687919302320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0076687919302320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T23:55:53Z","timestamp":1663718153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0076687919302320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128186718"],"references-count":60,"URL":"https:\/\/doi.org\/10.1016\/bs.mie.2019.05.051","relation":{},"ISSN":["0076-6879"],"issn-type":[{"value":"0076-6879","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}